The Congressionally Directed Medical Research Programs (CDMRP) has announced nearly $1.3 billion in funding across 34 research programs for Fiscal Year 2026, restoring topline support to near FY24 levels. This expansive portfolio includes major investments in cancer, neurological disorders, military health, and translational medical research—presenting a significant opportunity for investigators across Engineering and Health Sciences.
Notable FY26 allocations include:
- Peer Reviewed Medical Research Program (52 topics): $370M
- Peer Reviewed Cancer Research Program (20 topics): $165M
- Breast Cancer Research Program: $145M
- Prostate Cancer Research Program: $75M
- Ovarian, Pancreatic, Lung, Melanoma, and Rare Cancers: $147.5M combined
- Neurological & Psychological Health Programs (ALS, MS, Parkinson’s, TBI, SCI, Epilepsy): over $170M
Pre-announcements and funding opportunity announcements will be released on a rolling basis by CDMRP.
To support investigators interested in pursuing these opportunities, the AM&E Lab and LIFT teams will host CDMRP proposal development workshops every other Thursday, beginning February 12 (2:30–4:00 PM) in the HELIX Building, with Zoom options available. Sessions will feature structured discussions by topic area, subject-matter experts, and peer insight from successful CDMRP investigators.
RSVP here for the CDMRP proposal development workshops
Learn more about the FY26 CDMRP portfolio here:
https://cdmrp.health.mil/pubs/press/2026/FY26_Appropriations.aspx
